703 related articles for article (PubMed ID: 29321659)
1. Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies.
An Z; Aksoy O; Zheng T; Fan QW; Weiss WA
Oncogene; 2018 Mar; 37(12):1561-1575. PubMed ID: 29321659
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor as a therapeutic target in glioblastoma.
Kalman B; Szep E; Garzuly F; Post DE
Neuromolecular Med; 2013 Jun; 15(2):420-34. PubMed ID: 23575987
[TBL] [Abstract][Full Text] [Related]
3. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance.
Hatanpaa KJ; Burma S; Zhao D; Habib AA
Neoplasia; 2010 Sep; 12(9):675-84. PubMed ID: 20824044
[TBL] [Abstract][Full Text] [Related]
5. The EGFRvIII variant in glioblastoma multiforme.
Gan HK; Kaye AH; Luwor RB
J Clin Neurosci; 2009 Jun; 16(6):748-54. PubMed ID: 19324552
[TBL] [Abstract][Full Text] [Related]
6. A Rational Approach to Target the Epidermal Growth Factor Receptor in Glioblastoma.
Kwatra MM
Curr Cancer Drug Targets; 2017; 17(3):290-296. PubMed ID: 28029074
[TBL] [Abstract][Full Text] [Related]
7. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.
Camorani S; Crescenzi E; Colecchia D; Carpentieri A; Amoresano A; Fedele M; Chiariello M; Cerchia L
Oncotarget; 2015 Nov; 6(35):37570-87. PubMed ID: 26461476
[TBL] [Abstract][Full Text] [Related]
8. Molecular characterization of EGFR and EGFRvIII signaling networks in human glioblastoma tumor xenografts.
Johnson H; Del Rosario AM; Bryson BD; Schroeder MA; Sarkaria JN; White FM
Mol Cell Proteomics; 2012 Dec; 11(12):1724-40. PubMed ID: 22964225
[TBL] [Abstract][Full Text] [Related]
9. The TICking clock of EGFR therapy resistance in glioblastoma: Target Independence or target Compensation.
Saleem H; Kulsoom Abdul U; Küçükosmanoglu A; Houweling M; Cornelissen FMG; Heiland DH; Hegi ME; Kouwenhoven MCM; Bailey D; Würdinger T; Westerman BA
Drug Resist Updat; 2019 Mar; 43():29-37. PubMed ID: 31054489
[TBL] [Abstract][Full Text] [Related]
10. De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients.
Akhavan D; Pourzia AL; Nourian AA; Williams KJ; Nathanson D; Babic I; Villa GR; Tanaka K; Nael A; Yang H; Dang J; Vinters HV; Yong WH; Flagg M; Tamanoi F; Sasayama T; James CD; Kornblum HI; Cloughesy TF; Cavenee WK; Bensinger SJ; Mischel PS
Cancer Discov; 2013 May; 3(5):534-47. PubMed ID: 23533263
[TBL] [Abstract][Full Text] [Related]
11. Targeting LRIG2 overcomes resistance to EGFR inhibitor in glioblastoma by modulating GAS6/AXL/SRC signaling.
Dong M; Xiao Q; Hu J; Cheng F; Zhang P; Zong W; Tang Q; Li X; Mao F; He Y; Yu X; Wan F; Lei T; Guo D; Wang B
Cancer Gene Ther; 2020 Dec; 27(12):878-897. PubMed ID: 31988476
[TBL] [Abstract][Full Text] [Related]
12. Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells.
Hu J; Jo M; Cavenee WK; Furnari F; VandenBerg SR; Gonias SL
Proc Natl Acad Sci U S A; 2011 Sep; 108(38):15984-9. PubMed ID: 21896743
[TBL] [Abstract][Full Text] [Related]
13. The EGFR variant III mutant as a target for immunotherapy of glioblastoma multiforme.
Chistiakov DA; Chekhonin IV; Chekhonin VP
Eur J Pharmacol; 2017 Sep; 810():70-82. PubMed ID: 28583430
[TBL] [Abstract][Full Text] [Related]
14. Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in
Felsberg J; Hentschel B; Kaulich K; Gramatzki D; Zacher A; Malzkorn B; Kamp M; Sabel M; Simon M; Westphal M; Schackert G; Tonn JC; Pietsch T; von Deimling A; Loeffler M; Reifenberger G; Weller M;
Clin Cancer Res; 2017 Nov; 23(22):6846-6855. PubMed ID: 28855349
[No Abstract] [Full Text] [Related]
15. Simultaneous detection of EGFR amplification and EGFRvIII variant using digital PCR-based method in glioblastoma.
Fontanilles M; Marguet F; Ruminy P; Basset C; Noel A; Beaussire L; Viennot M; Viailly PJ; Cassinari K; Chambon P; Richard D; Alexandru C; Tennevet I; Langlois O; Di Fiore F; Laquerrière A; Clatot F; Sarafan-Vasseur N
Acta Neuropathol Commun; 2020 Apr; 8(1):52. PubMed ID: 32303258
[TBL] [Abstract][Full Text] [Related]
16. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens.
Feldkamp MM; Lala P; Lau N; Roncari L; Guha A
Neurosurgery; 1999 Dec; 45(6):1442-53. PubMed ID: 10598712
[TBL] [Abstract][Full Text] [Related]
17. Targeting ErbB receptors in high-grade glioma.
Berezowska S; Schlegel J
Curr Pharm Des; 2011; 17(23):2468-87. PubMed ID: 21827413
[TBL] [Abstract][Full Text] [Related]
18. Neutralizing the EGF receptor in glioblastoma cells stimulates cell migration by activating uPAR-initiated cell signaling.
Hu J; Muller KA; Furnari FB; Cavenee WK; VandenBerg SR; Gonias SL
Oncogene; 2015 Jul; 34(31):4078-88. PubMed ID: 25347738
[TBL] [Abstract][Full Text] [Related]
19. EGFRvIII-Stat5 Signaling Enhances Glioblastoma Cell Migration and Survival.
Roos A; Dhruv HD; Peng S; Inge LJ; Tuncali S; Pineda M; Millard N; Mayo Z; Eschbacher JM; Loftus JC; Winkles JA; Tran NL
Mol Cancer Res; 2018 Jul; 16(7):1185-1195. PubMed ID: 29724813
[TBL] [Abstract][Full Text] [Related]
20. Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models.
Keir ST; Chandramohan V; Hemphill CD; Grandal MM; Melander MC; Pedersen MW; Horak ID; Kragh M; Desjardins A; Friedman HS; Bigner DD
J Neurooncol; 2018 Jul; 138(3):489-498. PubMed ID: 29564747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
